All Stories

  1. Risk–Benefit Trade-offs of GLP-1RAs and SGLT-2is in Type 2 Diabetes Mellitus (T2D): Systematic Review, Meta-Analysis, and Net Benefit Modeling

    Article • Diabetes Therapy, November 2025, Springer Science + Business Media

    Dr Samit Ghosal

  2. Effects of Lifestyle and GLP-1RA based Interventions on Waist Circumference: A Systematic Review and Meta-Analysis

    Article • August 2025, International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)

    Dr Samit Ghosal

  3. Unveiling the Power of GLP-1RAs: Optimizing MACE Reduction in T2DM Through BMI and Blood Pressure Insights

    Article • August 2025, International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)

    Dr Samit Ghosal

  4. Understanding Weight Loss Treatments: Comparing New Medications for Obesity Management

    Article • Obesity, July 2025, Wiley

    Dr Samit Ghosal

  5. Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study

    Article • Diabetes Therapy, August 2024, Springer Science + Business Media

    Dr Samit Ghosal

  6. Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study

    Article • June 2024, International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)

    Dr Samit Ghosal

  7. The Renal Composite Benefit of Sodium Glucose Co-Transporter 2 Inhibitors Should Ideally Be Assessed Based on a Standardised Definition: A Meta-Analysis of Randomised Controlled Trials

    Article • Journal of Clinical Medicine, October 2023, MDPI AG

    Dr Samit Ghosal

  8. Guide to Better Meta-Analysis: Checklists for Reviewers.

    Article • May 2023, MDPI AG

    Dr Samit Ghosal

  9. Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight

    Article • ESC Heart Failure, January 2023, Wiley

    Dr Samit Ghosal

  10. Assessing the Effects of Modern Renoprotective Agents in Preventing Progression of Renal Composite Outcomes in Patients with Type 2 Diabetes: A Network Meta-analysis

    Article • Diabetes Therapy, December 2022, Springer Science + Business Media

    Dr Samit Ghosal

  11. Using machine learning to assess cardiovascular risk in T2DM patients without established cardiovascular disease: The MARK-2 analysis

    Article • April 2022, Research Square

    Dr Samit Ghosal

  12. A Meta-Analysis of the Effect of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic Parameters in Patients With Polycystic Ovary Syndrome

    Article • Frontiers in Endocrinology, February 2022, Frontiers

    Dr Samit Ghosal

  13. The cardiovascular benefits of GLP1-RAs are related to their positive effect on glycemic control: A meta-regression analysis

    Article • February 2022, Research Square

    Dr Samit Ghosal

  14. The cardiovascular benefits of GLP1-RA are directly related to their positive effect on glycaemic control: A meta-regression analysis

    Article • January 2022, International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)

    Dr Samit Ghosal

  15. A meta-analysis of the effect of sodium glucose cotransporter-2 inhibitors (SGLT-2is) on metabolic parameters in patients with polycystic ovary syndrome (PCOS)

    Article • August 2021, Research Square

    Dr Samit Ghosal

  16. Testosterone replacement therapy in men with type 2 diabetes mellitus and functional hypogonadism –an Integrated Diabetes and Endocrine Academy (IDEA) consensus guideline

    Article • Diabetes & Metabolic Syndrome Clinical Research & Reviews, July 2021, Elsevier

    Dr Samit Ghosal

  17. A Target HbA1c Between 7 and 7.7% Reduces Microvascular and Macrovascular Events in T2D Regardless of Duration of Diabetes: a Meta-Analysis of Randomized Controlled Trials

    Article • Diabetes Therapy, April 2021, Springer Science + Business Media

    Dr Samit Ghosal

  18. A target HbA1c between 7 – 7.7% reduces macrovascular events in T2D regardless of duration of diabetes – a meta-analysis of randomized controlled trials

    Article • March 2021, Cold Spring Harbor Laboratory Press

    Dr Samit Ghosal

  19. Meta‐analysis of the effects of sodium glucose cotransporter 2 inhibitors in non‐alcoholic fatty liver disease patients with type 2 diabetes

    Article • JGH Open, December 2020, Wiley

    Dr Samit Ghosal

  20. Redefining Cardiovascular (CV) Death as a Primary Endpoint Component in Cardiovascular Outcome Trials

    Article • Current Diabetes Reviews, November 2020, Bentham Science Publishers

    Dr Samit Ghosal

  21. Increase in the risk of type 2 diabetes during lockdown for the COVID19 pandemic in India: A cohort analysis

    Article • Diabetes & Metabolic Syndrome Clinical Research & Reviews, September 2020, Elsevier

    Dr Samit Ghosal

  22. “Compliance of the Indian National Task Force guidelines for COVID-19 recommendation by Indian doctors – A survey"

    Article • Diabetes & Metabolic Syndrome Clinical Research & Reviews, September 2020, Elsevier

    Dr Samit Ghosal

  23. Estimation of effects of nationwide lockdown for containing coronavirus infection on worsening of glycosylated haemoglobin and increase in diabetes-related complications: A simulation model using multivariate regression analysis

    Article • Diabetes & Metabolic Syndrome Clinical Research & Reviews, July 2020, Elsevier

    Dr Samit Ghosal

  24. Impact of complete lockdown on total infection and death rates: A hierarchical cluster analysis

    Article • Diabetes & Metabolic Syndrome Clinical Research & Reviews, July 2020, Elsevier

    Dr Samit Ghosal

  25. Linear Regression Analysis to predict the number of deaths in India due to SARS-CoV-2 at 6 weeks from day 0 (100 cases - March 14th 2020)

    Article • Diabetes & Metabolic Syndrome Clinical Research & Reviews, July 2020, Elsevier

    Dr Samit Ghosal

  26. Rapid sputum testing and not thermal screening alone should be the first-line screening test at airports: A Bayesian analysis

    Article • Diabetes & Metabolic Syndrome Clinical Research & Reviews, July 2020, Elsevier

    Dr Samit Ghosal

  27. Is it Worth CANVASing for CREDENCE? A Benefit-risk Analysis

    Article • Current Diabetes Reviews, May 2020, Bentham Science Publishers

    Dr Samit Ghosal

  28. Impact of complete lock-down on total infection and death rates: A hierarchical cluster analysis

    Article • May 2020, Cold Spring Harbor Laboratory Press

    Dr Samit Ghosal

  29. Translating the statistical benefits of SGLT-2 inhibitors on cardio-renal outcomes into clinical practice

    Article • Expert Review of Clinical Pharmacology, April 2020, Taylor & Francis

    Dr Samit Ghosal

  30. The effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on death and severity of disease in patients with coronavirus disease 2019 (COVID-19): A meta-analysis

    Article • April 2020, Cold Spring Harbor Laboratory Press

    Dr Samit Ghosal

  31. The role of corticosteroids in the management of critically ill patients with coronavirus disease 2019 (COVID-19): A meta-analysis

    Article • April 2020, Cold Spring Harbor Laboratory Press

    Dr Samit Ghosal

  32. Frequency of testing for COVID 19 infection and the presence of higher number of available beds per country predict outcomes with the infection, not GDP of the country – A descriptive statistical analysis

    Article • April 2020, Cold Spring Harbor Laboratory Press

    Dr Samit Ghosal

  33. Quantitative measure of asymptomatic cardiovascular disease risk in Type 2 diabetes: Evidence from Indian outpatient setting

    Article • Indian Heart Journal, March 2020, Elsevier

    Dr Samit Ghosal

  34. Teneligliptin and “Thorough QTc study”: thorough enough?

    Article • Diabetes Metabolic Syndrome and Obesity, July 2019, Dove Medical Press

    Dr Samit Ghosal

  35. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure

    Article • Diabetes Research and Clinical Practice, April 2019, Elsevier

    Dr Samit Ghosal

  36. Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis

    Article • Diabetes Therapy, March 2019, Springer Science + Business Media

    Dr Samit Ghosal

  37. Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study

    Article • Clinical Diabetes and Endocrinology, May 2018, Springer Science + Business Media

    Dr Samit Ghosal

  38. Hypoglycaemia and CV risk: Perceptions and reality

    Article • Diabetes & Metabolic Syndrome Clinical Research & Reviews, October 2015, Elsevier

    Dr Samit Ghosal

  39. Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Some case reports from India

    Article • Diabetes Metabolic Syndrome and Obesity, June 2014, Taylor & Francis

    Dr Samit Ghosal, Kalyan Gangopadhyay

  40. India suspends pioglitazone: Is it justified?

    Article • Diabetes & Metabolic Syndrome Clinical Research & Reviews, January 2014, Elsevier

    Dr Samit Ghosal

  41. Treat-to-target trials in diabetes

    Article • Indian Journal of Endocrinology and Metabolism, January 2014, Medknow

    Dr Samit Ghosal

  42. Pioglitazone – Do we really need it to manage type 2 diabetes?

    Article • Diabetes & Metabolic Syndrome Clinical Research & Reviews, October 2013, Elsevier

    Dr Samit Ghosal

  43. Polyendocrine syndromes (revision number 19)

    Article • March 2013, Diapedia

    Dr Samit Ghosal

  44. Hyperprolactinaemia (revision number 8)

    Article • March 2013, Diapedia

    Dr Samit Ghosal

  45. Pioglitazone—Do we really need it to manage type 2 diabetes?

    Article • Diabetes & Metabolic Syndrome Clinical Research & Reviews, January 2013, Elsevier

    Dr Samit Ghosal

  46. Hypercortisolism (revision number 36)

    Article • October 2012, Diapedia

    Dr Samit Ghosal

  47. Quantitative vibration perception threshold in assessing diabetic neuropathy: Is the cut-off value lower for Indian Subjects? [Q-VADIS Study]

    Article • Diabetes & Metabolic Syndrome Clinical Research & Reviews, April 2012, Elsevier

    Dr Samit Ghosal

  48. Critical appraisal of the recent data published on the link between insulin and cancer

    Article • Diabetes & Metabolic Syndrome Clinical Research & Reviews, October 2011, Elsevier

    Dr Samit Ghosal, Moien AB Khan